Abdolmohamad Rostami, MD, PhD

Professor
Chairman, Department of Neurology
Director, Neuroimmunology Laboratory

Abdolmohamad Rostami, MD, PhD

Contact

901 Walnut Street
Suite 400
Philadelphia, PA 19107

Email Abdolmohamad Rostami

215-955-8100
215-955-1390 fax

Abdolmohamad Rostami, MD, PhD

Professor
Chairman, Department of Neurology
Director, Neuroimmunology Laboratory

Education

Medical School

MD, Shiraz University, Iran                                                                        , 

PhD, University of Pennsylvania 

Residency

Hospital of University of Pennsylvania (HUP)

Fellowship

Hospital of University of Pennsylvania (HUP)

Publications

Board Certification

Neurology

Hospital Appointment

Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

Research & Clinical Interests

Multiple Sclerosis is an autoimmune disease of the central nervous system that affects over 400,000 Americans and over two million worldwide. My research focuses on the pathogenesis of multiple sclerosis using the animal model of this disease, experimental autoimmune encephalomyelitis (EAE). At the present, we are focusing on three main areas:

  1. The role of IL-12/IL-17/IL-23 axis in the pathogenesis of EAE and multiple sclerosis.
    Specifically, studies will examine IL-12/IL-17/IL-23 produced by antigen presenting cells (APC) from the periphery (macrophages and dendritic cells) and from the central nervous system (CNS) microglia in EAE. In addition to a better understanding of the pathogenesis of inflammatory demyelination, the information derived from this study will be helpful if these cytokines are to be considered as targets for therapy in MS.
  2. The effect of the Bowman-Birk protease inhibitor on the course of EAE.
    This study has the potential to provide a novel, safe, and effective therapy for multiple sclerosis.
  3. Mechanisms of intravenous tolerance in EAE.
    This study will elucidate the mechanisms by which intravenous myelin antigens induce tolerance and suppress clinical disease in EAE. This study will provide a novel method for analyzing the migration and functional status of infiltrating cells in the CNS, in particular, and in target organs of other autoimmune diseases. It has the potential as a possible therapy for autoimmune diseases.